Edit
Twentyeight-Seven Therapeutics (28-7)
https://www.twentyeight-seven.com/Last activity: 18.05.2023
Active
28-7 Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.
Total raised: $80M
Founded date: 2016
Investors 4
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | Sofinnova ... | sofinnovap... |
| - | BioImpact ... | bioimpactc... |
| - | MPM BioImp... | mpmbioimpa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.05.2019 | Series A | $15M | - |
| 06.09.2018 | Series A | $65M | - |
Mentions in press and media 7
| Date | Title | Description |
| 10.05.2019 | Term Sheet — Friday, May 10 | RINGING THE BELL Uber CEO Dara Khosrowshahi rang the bell this morning in a historic IPO for the tech world. After a decade, the ride-hailing giant is finally making its debut on the public markets. Paid Content What you need to know about ... |
| 09.05.2019 | Twentyeight-Seven Therapeutics Raises $15M Series A Extension | Twentyeight-Seven Therapeutics, a Watertown, MA-based biotechnology company focused on the modulation of RNA to treat cancer and other human diseases, raised $15m in a Series A extension round. The extension round, which brought the total S... |
| 07.09.2018 | Term Sheet — Friday, September 7 | THREE THINGS Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop THE LATEST IN ELON MUSK: Well, um, how do I put this? In a spectacularly bold move after everything that’s happened, Tesla CEO... |
| 06.09.2018 | 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA | Twentyeight-Seven Therapeutics has launched with $65 million in venture capital to fund its treatments for a variety of cancers, which aim to modulate noncoding strands of microRNA to increase the levels of tumor-suppressing genes. The Camb... |
| 06.09.2018 | Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Twentyeight-Seven Therapeutics (28-7), a biotechnology company focused on modulating non-coding RNA (ncRNA) biology to develop treatments for cancer and other diseases, today announced the successful compl... |
| 06.09.2018 | Twentyeight-Seven Therapeutics Launches with $65M in Series A Funding | Twentyeight-Seven Therapeutics (28-7), a Cambridge, Mass.-based biotechnology company focused on modulating non-coding RNA (ncRNA) biology to develop treatments for cancer and other diseases, closed a $65m Series A financing. The round was ... |
| 06.09.2018 | 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA | Twentyeight-Seven Therapeutics has launched with $65 million in venture capital to fund its treatments for a variety of cancers, which aim to modulate noncoding strands of microRNA to increase the levels of tumor-suppressing genes. Sponsore... |